Medical Device Developments Weekly
Medical Device Developments
Latest news and insight on innovations in the Medical Device sector.
Welcome to this week's Medical Device Developments newsletter.
See the latest insight and analysis from the global medical device market from the last week below:
Reflow Medical recruits first patient in Spur Elute trial for in-stent restenosis
The study, known as DEEPER CORONARY, will recruit 10 patients at up to three centres in New Zealand.
New Zealand’s Wellington Hospital interventional cardiologist and trial principal investigator Scott Harding said: “It’s exciting to take part in the study of this novel platform, which has the potential to successfully treat patients suffering from in-stent restenosis.”
SpineCraft and Spartan Medical Inc. announce strategic partnership
This partnership announcement furthers an existing relationship and collaboration between the two organizations, expanding access to SpineCraft’s portfolio to physicians and patients at VA and DoD medical facilities worldwide.
“As the spinal industry has evolved, we’ve seen an exponential race to the bottom driven by lower cost demands from hospital systems and group purchasing organizations (GPOs),” said Vince Proffitt, Founder & President of Spartan Medical Inc..
Avicenna.AI secures MDR certification for its AI imaging portfolio
The certification was granted by BSI Medical Devices, an EU Notified Body that provides quality management reviews and CE certifications for medical device manufacturers around the world.
With the MDR certification, the company’s product portfolio becomes fully compliant with the EU MDR 2017/745 regulation, which is now mandatory for medical device companies in Europe.
KORU Medical Systems’s FreedomEdge syringe infusion system approved in Japan
领英推荐
The infusion system is indicated for the delivery of multiple drugs, including CSL Behring’s Hizentra, Takeda’s Cuvitru SCIg, and Sobi’s Aspaveli.
According to KORU Medical Systems, the regulatory approval marks a significant advancement in patient care in Japan.
SOPHiA GENETICS integrates Dhiti Omics on SOPHiA DDM Platform
The SOPHiA DDM Platform analyses complex genomic and multimodal data to deliver real-time, actionable insights to a diverse global network including hospitals, laboratories, and biopharma institutions.
Dhiti Omics will use the SOPHiA DDM Platform technology to improve its solid tumour testing capabilities.
Carmat secures equity financing from Vester Finance SA for artificial heart
The French medical technology firm designs, manufactures, and markets the Aeson artificial heart.
The agreement with Vester Finance SA allows for the issuance of a maximum of 3.5 million shares over 24 months. Under the deal, Vester Finance will subscribe to CARMAT’s ordinary shares at a maximum of 9.96% of the latter’s current share capital
Recommended webinars
Thanks for reading; we hope you enjoyed it.
Until next week.
To have a story featured on next week's newsletter - contact Medical Device Developments or Jamie Mann directly.
#MedicalDeviceDevelopments